Hansa Biopharma — December 2025
-
Hansa Biopharma: Negative anti-GBM Phase III Readout
.. "The relative valuation of anti-GBS was comparatively modest in our base case at around SEK8 per share. We therefore view this negative outcome as a moderate setback, given the significantly larger kidney indication." ..
-
-
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind